PHARMACY POLICY STATEMENT
Marketplace

DRUG NAME	Daybue (trofinetide)
BENEFIT TYPE	Pharmacy
STATUS	Prior Authorization Required

Daybue is an insulin-like growth factor-1 (IGF-1) analog of glycine-proline-glutamate (GPE) that was FDA approved for the treatment of Rett syndrome in March 2023. Rett syndrome is a rare, debilitating neurodevelopmental disorder that affects the way the brain develops. The condition is characterized by a

For **reauthorization**:

1. Chart notes must show improvement or stabilized signs and symptoms of disease demonstrated by improvement or stabilization on the Rett Syndrome Behavior Questionnaire (RSBQ) or the Clinical Global Impression-Improvement (CGI-I) score

If all the above requirements are met, the medication will be approved for an additional 12 months.

CareSource considers Daybue (trofinetide) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

DATE	